Stay updated on Ponatinib for Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Ponatinib for Medullary Thyroid Cancer Clinical Trial page
- Check5 days agoChange DetectedThe displayed ClinicalTrials.gov site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check12 days agoChange DetectedA sitewide notice announces NIH website updates and explains that some content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check19 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the study page continues to display a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates an accessibility issue rather than a substantive content update, leaving the page in an error state.SummaryDifference17%

- Check68 days agoChange DetectedRevision: v3.6.6 is now shown, replacing v3.6.5. This indicates an internal page or template update rather than any changes to the study details, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to Ponatinib for Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.